Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

While both are called medullary carcinoma, these cancers differ in many ways: ...

Colorectal cancer is a term that combines both colon and rectal cancers. The colon and rectum are two different parts of the ...

Researchers at Karolinska Institutet, led by Dr. Helin Norberg and Dr. Erik Norberg, have identified a previously unknown ...

Cancer-associated fibroblasts (CAFs) play an important role in metastatic melanoma, and an enhanced understanding of that role could lead to important new therapeutic pathways, according to a new ...

Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the United States, is increasingly linked to ...

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

mRCC, metastatic renal cell carcinoma; OS, overall survival; PFS, progression-free survival. Primary insurance status was categorized into three groups—patients with Medicare, private insurance, and ...

We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC. Patients and Methods: Patients with metastatic RCC were infused ...